MDS Nordion Opens New Radiopharmaceutical Production Facility in Belgium

Ottawa, Canada and Fleurus, Belgium (ots/PRNewswire) -

- Site to Provide Fluorodeoxyglucose (F-18 FDG) for use in
Earlier Detection of Disease and Therapy Management

MDS Nordion, a leading global provider of medical isotopes and
radiopharmaceuticals used in molecular medicine, today announced the
opening of a facility in Fleurus, Belgium for the production of
Fluorodeoxyglucose (F-18 FDG), a radiopharmaceutical used in positron
emission tomography (PET) imaging.

PET imaging produces a three-dimensional image, or picture, of
functional processes in the body, such as brain activity, and is a
highly accurate and effective method of diagnosing disease and
managing patient therapy. MDS Nordion's new facility will provide
timely supply of F-18 FDG to hospitals throughout Belgium, France,
The Netherlands, Luxembourg and Germany.

"Customers count on MDS Nordion for leadership, quality products
and customized services," said Steve West, President MDS Nordion.
"Our investment in this facility further demonstrates our commitment
to address the growing demand for PET diagnostic imaging in targeted
European regions, and provides the medical community greater service
for their future patient care."

The PET imaging market is the most rapidly growing area of
nuclear medicine and procedures. Statistics from a recent Medical
Options survey indicates PET examinations are on a rapid rise in
Europe, and are expected to grow at a compound annual rate of
approximately 20% through 2012. To help meet increasing demand, this
state-of-the-art, Good Manufacturing Practice (GMP) production
facility will have three daily production runs and a customer service
team available 24 hours a day, seven days a week.

"PET imaging is effective because it allows early detection of
tumours, as well as assessment of therapeutic strategies," said
Professor Roland Hustinx, Nuclear Medicine Department, CHU -
Universite de Liege. "In particular, MDS Nordion's new facility will
provide another source of supply of F-18 FDG to existing and new
medical facilities, thereby increasing the ability of health-care
practitioners to conduct this critical type of imaging."

About MDS Nordion

MDS Nordion, a business unit of MDS Inc., is a global leader in
providing medical isotopes for molecular and diagnostic imaging,
radiotherapeutics and sterilization technologies for medical products
that benefit the lives of millions of people in more than 50
countries around the world. MDS Nordion's products and services are
used on a daily basis by pharmaceutical and biotechnology companies,
medical-device manufacturers, hospitals, clinics and research
laboratories. Find out more at http://www.mdsnordion.com

About MDS

MDS Inc. (TSX: MDS; NYSE: MDZ) is a global life sciences company
that provides market-leading products and services that our customers
need for the development of drugs, and the diagnosis and treatment of
disease. We are a leading global provider of pharmaceutical contract
research, medical isotopes for molecular imaging, radiotherapeutics,
and analytical instruments. MDS has more than 5,000 highly skilled
people in 29 countries. Find out more at http://www.mdsinc.com.

ots Originaltext: MDS
Im Internet recherchierbar: http://www.presseportal.de

Contact:
CONTACT MDS Nordion: MEDIA: Shelley Maclean, +1-613-291-3689,
shelley.maclean@mdsinc.com; VPR Consult: Carl Bosteels,
+32-473-68-28-50, carl.bosteels@vprconsult.be; INVESTORS: Kim Lee,
+1-416-213-4721, kim.lee@mdsinc.com